Effects of lasmiditan: A Synthesis of Findings from 16 Studies

  1. Home
  2. Effects of lasmiditan
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of lasmiditan: A Synthesis of Findings from 16 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of lasmiditan: A Synthesis of Findings from 16 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major research findings

Lasmiditan is a new type of migraine medication that may be used even by patients with cardiovascular disease or risk factors. 16 It has a different mechanism of action than triptans and does not affect the cardiovascular system, so it is a promising option for patients who cannot take triptans due to various reasons. 16

Lasmiditan has been reported to have fewer side effects than triptans. 1 However, like triptans, lasmiditan has been reported to have side effects such as drowsiness and nausea. 1

Lasmiditan may be less effective than triptans in treating migraines. 4 However, it may be an effective treatment option for patients who cannot take triptans. 5

Benefits and Risks

Benefits Summary

Lasmiditan is a new type of migraine medication that may be used even by patients with cardiovascular disease or risk factors. 16 It has been reported to have fewer side effects than triptans. 1

Risks Summary

Lasmiditan has been reported to have side effects such as drowsiness and nausea. 1 It may also be less effective than triptans. 4

Comparison between studies

Commonalities of studies

Studies consistently report that lasmiditan does not affect the cardiovascular system, unlike triptans. 16 2

Differences between studies

Studies have reported different results on the effectiveness of lasmiditan. 4 Some studies reported that lasmiditan was less effective than triptans. 4 Others reported that lasmiditan was as effective as triptans. 4

Consistency and inconsistency of results

The effectiveness of lasmiditan varies across studies. 4 This may be attributed to differences in study design and the patient population. Future research should involve a larger patient population and use a uniform study design to more clearly evaluate the effectiveness of lasmiditan.

Notes on application to daily life

Lasmiditan may be used by patients with cardiovascular disease or risk factors. 16 However, it may be less effective than triptans and has side effects such as drowsiness and nausea. 1 When considering lasmiditan, it is important to discuss these points with your doctor.

Limitations of current research

There are relatively few studies evaluating the effectiveness of lasmiditan, and more research is needed. The long-term safety of lasmiditan is also not well understood. Future research should investigate long-term safety, effectiveness, and interactions with other medications.

Future research directions

Large-scale clinical trials involving a larger number of patients are needed to more clearly evaluate the effectiveness and safety of lasmiditan. Research is also required to investigate long-term safety, effectiveness, and interactions with other medications.

Conclusion

Lasmiditan is a new type of migraine medication that may be used even by patients with cardiovascular disease or risk factors. 16 However, it may be less effective than triptans and has side effects. 4 It is important to discuss these points with your doctor when considering lasmiditan.

Literature analysis of 16 papers
Positive Content
16
Neutral Content
0
Negative Content
0
Article Type
3
4
2
6
16
2.

Profile of Lasmiditan in the Acute Treatment of Migraine in Adults: Design, Development, and Place in Therapy.

Author: AndersonChristopher C, VanderPluymJuliana H

Migraine relief
Vasoconstriction

Lasmiditan, a first-in-class 5-HT1F receptor agonist, is a new treatment for acute migraine attacks. Lasmiditan offers a novel therapeutic approach with a favorable side effect profile, providing an alternative for patients who cannot tolerate triptans.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

4.

Efficacy, safety and indirect comparisons of lasmiditan, rimegepant, and ubrogepant for the acute treatment of migraine: A systematic review and network meta-analysis of the literature.

Author: PuleddaFrancesca, YounisSamaira, HuesslerEva-Maria, HaghdoostFaraidoon, LisickiMarco, GoadsbyPeter J, TassorelliCristina

Migraine treatment
Ubrogepant tolerability
Dizziness
Nausea
Somnolence

This network meta-analysis compared the efficacy and safety of newly developed drugs for acute migraine treatment: lasmiditan, rimegepant, and ubrogepant. Lasmiditan was found to be most effective but had higher rates of dizziness, nausea, and somnolence. Rimegepant had similar efficacy but with less adverse effects. Ubrogepant had the best tolerability profile. The study concluded that lasmiditan is the most effective but less tolerable, rimegepant is similarly effective but with fewer side effects, and ubrogepant has the best tolerability.

Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

5.

Place of next generation acute migraine specific treatments among triptans, non-responders and contraindications to triptans and possible combination therapies.

Author: de BoerIrene, VerhagenIris Elsa, SouzaMarcio Nattan Portes, AshinaMessoud

migraine treatment
cardiovascular safety
medication overuse headache

This review summarizes the literature on next-generation acute migraine therapies, including ditans (lasmiditan) and gepants (rimegepant and ubrogepant), as alternatives to triptans. While the new therapies show promise, head-to-head trials are needed to determine their place in migraine treatment.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

6.

Lasmiditan abortive therapy for episodic migraine in Phase II/III randomized clinical trials: A meta-analysis.

Author: AhsanMarya, MallickAyaz Khurram

Migraine treatment

This meta-analysis and trial sequential analysis (TSA) assesses the efficacy and tolerability of lasmiditan, a specific 5-HT1F agonist, for treating episodic migraine. Lasmiditan is a new treatment option for migraine.

Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

7.

Headache: Treatment update.

Author: OgunlajaOyindamola I, GoadsbyPeter J

Migraine treatment

This article provides an overview of the new treatments available for migraine, a common cause of disability worldwide. The article discusses the benefits and limitations of different drug classes, including 5HT1F receptor agonists (ditans), small molecule CGRP receptor antagonists (gepants), and anti-CGRP monoclonal antibodies.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

8.

Rimegepant, Ubrogepant, and Lasmiditan in the Acute Treatment of Migraine Examining the Benefit-Risk Profile Using Number Needed to Treat/Harm.

Author: JohnstonKarissa M, PowellLauren, PopoffEvan, HarrisLinda, CroopRobert, CoricVladimir, L'ItalienGilbert

Pain freedom
Pain relief
Dizziness
Nausea

This network meta-analysis of 5 randomized controlled trials compared the benefit-risk profiles of three migraine treatments: rimegepant, ubrogepant, and lasmiditan. Rimegepant and ubrogepant were the most effective treatments for sustained pain relief. Ubrogepant had the highest number needed to harm for dizziness and nausea.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

9.

Safety Findings in Lasmiditan as a Novel Acute Treatment of Migraine in Chinese Patients: A Post Hoc Analysis of the Randomized Controlled Phase 3 CENTURION Trial.

Author: ZhouJiying, LuoGuogang, XuYuming, YangXiaosu, PanXiaoping, DongZhao, ZhongShiying, LiuHui, JiFei, YuShengyuan

Migraine treatment

Lasmiditan, a 5-HT1F receptor agonist, is a potential treatment for migraine. This post-hoc analysis of the CENTURION study demonstrates the safety profile of lasmiditan in a Chinese population.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

10.

New Oral Drugs for Migraine.

Author: KarsanNazia, GoadsbyPeter J

Migraine treatment
Medication overuse
Vasoconstrictive effects

Migraine treatment has seen significant advancements in recent years, with targeted therapies for both acute and preventive treatment emerging. The study discusses the evolution of oral migraine treatments over the past five years, highlighting new medications and potential future targets.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

11.

Ditans: a new prospective for the therapy of migraine attack?

Author: ViticchiGiovanna, FalsettiLorenzo, SilvestriniMauro, BartoliniMarco

Migraine treatment

Migraines are severe headaches that can be debilitating. This article discusses the use of "ditans," a new class of medications for treating migraines, and focuses on lasmiditan, a ditan that is currently available for use.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

12.

Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings.

Author: PolaviejaPepa, BelgerMark, VenkataShiva Kumar, WilhelmStefan, JohanssonErin

Acute migraine treatment
Lasmiditan for migraine
Rimegepant for migraine
Ubrogepant for migraine

This network meta-analysis explored the relative efficacy of lasmiditan versus rimegepant and ubrogepant for acute migraine treatment.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

14.

Lasmiditan for single migraine attack in Japanese patients with cardiovascular risk factors: subgroup analysis of a phase 2 randomized placebo-controlled trial.

Author: HashimotoYoichiro, KomoriMika, TanjiYuka, OzekiAkichika, HirataKoichi

Effective migraine treatment
Cardiovascular adverse events
Hypertension

Lasmiditan, a new oral acute migraine treatment without cardiovascular contraindications, is well-tolerated and effective for Japanese patients with migraine and cardiovascular risk factors (CVRFs). A phase 2 study found no relationship between the number of CVRFs and the incidence of treatment-emergent adverse events, and lasmiditan was effective in relieving pain, symptoms, and disability regardless of the number of CVRFs.

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

15.

Safety profile of lasmiditan in patients with migraine in an Asian population.

Author: HirataKoichi, MatsumoriYasuhiko, TanjiYuka, KhannaRashna, OzekiAkichika, KomoriMika

Effective migraine treatment
Common adverse events

This article examines the safety profile of lasmiditan, a migraine medication, based on data from the MONONOFU study conducted in Japan. The study found that treatment-emergent adverse events were more common in Japanese patients than in global studies, highlighting the need for a detailed safety profile to assist in patient management.

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

16.

Lasmiditan for Patients with Migraine and Contraindications to Triptans: A Post Hoc Analysis.

Author: KregeJohn H, LiptonRichard B, BayganiSimin K, KomoriMika, RyanSinéad M, VincentMaurice

Improved migraine treatment
Reduced cardiovascular risk

This post-hoc analysis evaluated the efficacy and safety of lasmiditan, a selective 5-HT<sub>1F</sub> receptor agonist, in patients with and without triptan contraindications.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.